(Q36773460)

16 August 2017

1 reference

title

Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing (English)

1 reference

16 August 2017

1 reference

cervix uterine cancer

1 reference

inferred from title

human papilloma virus

1 reference

human papillomavirus

29 September 2024

Cosette M Wheeler

1

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

published in

1 reference

16 August 2017

volume

4

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

224-235

1 reference

Evaluating human papillomavirus vaccination programs

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Cervical cancer screening: which techniques should be used and why?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

The screening histories of women with invasive cervical cancer, Connecticut

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Cervical Cancer in Women With Comprehensive Health Care Access: Attributable Factors in the Screening Process

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Social inequities along the cervical cancer continuum: a structured review

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Pap smear noncompliance among female obstetrics-gynecology residents

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Pain predicts non-adherence to pap smear screening among middle-aged African American women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Papillomaviruses and cancer: from basic studies to clinical application

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

The global health burden of infection-associated cancers in the year 2002

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Classification of papillomaviruses

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Vaccination to prevent and treat cervical cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Efficacy and other milestones for human papillomavirus vaccine introduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Multiple sexual partners among U.S. adolescents and young adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Eyebrows raised over extended age range for cervical cancer vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Natural history of human papillomavirus type 16 virus-like particle antibodies in young women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Human papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0770

7 January 2021

Identifiers

DOI

10.1038/NCPONC0770

1 reference

16 August 2017

1 reference